Alembic Pharma’s revenue missed our estimates (-2.2%) due to weak growth in domestic and API business. EBITDA fell short of our estimates due to a miss in revenue and higher operating expenses. Adj. PAT missed our estimates due to higher-than-expected tax expenses and lower-than-expected other income.